IDEXX Laboratories Q3 revenue beats estimates, lifts FY profit outlook 

Overview

• U.S. pet diagnostics firm's Q3 revenue rose 10%, beating analyst expectations

• Q3 EPS increased 18% to $4.01

• Company raised 2026 revenue and EPS guidance on strong recurring revenue growth

Outlook

• IDEXX raises 2026 revenue outlook to $4.74 bln-$4.77 bln, up $32 mln at midpoint

• Company increases 2026 EPS guidance to $14.96-$15.16, up $0.25 from prior midpoint

• IDEXX lowers 2026 operating margin outlook to 32.1%-32.3% from previous 32.3%-32.5%

Result Drivers

• CAG DIAGNOSTICS RECURRING REVENUE - Double-digit growth driven by strong same-store volume, customer gains, and expanded instrument base

• INNOVATION AND PRODUCT LAUNCHES - New analyzers and expanded diagnostic panels contributed to revenue growth

• PRICE REALIZATION AND PRODUCTIVITY - Net price gains and operational productivity supported margin expansion

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for IDEXX Laboratories, Inc. is $707.50, about 28.4% above its October 30 closing price of $551.21

• The stock recently traded at 34 times the next 12-month earnings vs. a P/E of 36 three months ago

Reuters Recommended Reads

• Oct 30 - AstraZeneca CEO strikes bullish tone on pipeline as stock rallies

• Oct 30 - India orders Sun Pharma to halt eye-care drug production at plant after quality lapses

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)